Medscape: Booster shot back-and-forth creates uncertainty, confusion
UC expert says confusion about boosters could make some reluctant to get vaccinated
In the wake of recent announcements from the U.S. Food and Drug Administration and Centers for Disease Control and Prevention about who is authorized to get a third or 'booster' shot of the Pfizer/BioNTech COVID-19 vaccine, many people, patients and providers alike, are confused. In an article on the topic, Medscape interviewed Louito Edje, MD, associate dean of graduate medical education at the UC College of Medicine who said that confusion could make some people reluctant to get the vaccine.
Medscape reported that the confusion started, in part, with the August 13 announcement that immunocrompromised Ameriicans were eligible for a booster shot. Next came the initial Biden administration intention to provide most adults in the United States with a third shot starting September 20 — an announcement later rolled back — followed by the FDA and CDC limiting boosters to select groups last month.
"It was only 3% of the population that was going to be getting a third dose, then it was back to everyone being able to get the booster, and then it's back to a select crew," Edje told Medscape. This kind of mixed messaging is generating more questions than answers.
Louito Edje, MD, associate dean of graduate medical education at the UC College of Medicine/Photo/Colleen Kelley/UC Creative + Brand
"Even though that is following the science, translating the science into policy, it's really fraught with confusion for patients, especially," added Edje.
Edje shared an example. "The folks who have been hesitant to even get the first vaccine appear now a little less likely to want to go ahead and get vaccinated."
These patients point to breakthrough COVID-19 cases of the Delta variant, which "reinforces that they don't need to get vaccinated in the first place," Edje said. "That's unfortunate because it's a complete fallacy."
Edje said she is seeing an increasing interest among patients in getting the booster shot.
"I take care of a fair number of folks...including the elderly and healthcare professionals. They are already asking for the booster."
Interestingly, Edje would like to get a booster herself but is not eligible for the Pfizer third shot. She is a participant in a Moderna vaccine trial and can only receive additional immunization as part of the study.
Lead photo/Colleen Kelley/UC Creative + Brand
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.